For previously treated RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer, the ORR was 64%, 69% (1-year PFS of 82%), and 79% (1-year PFS of 64%). This evidence concerns the gene RET and non-small cell lung carcinoma.